ARYx Therapeutics, Inc.
ARYx Announces Resignation of Peter G. Milner, President Research and Development
Published in Mental Health Business Week, June 19th, 2010
ARYx Therapeutics, Inc. (NASDAQ:ARYX) announced that Peter G. Milner, M.D., has resigned, effective June 15, 2010, as a director and as president research and development. He will continue to consult to the company in support of ARYx's on-going strategic process. Dr. Milner, along with Dr. Pascal Druzgala, co-founded ARYx in 1997 in pursuit of novel therapies that avoid known safety concerns with previously commercialized pharmaceuticals. Based upon ARYx's unique drug discovery approach, the company now has three late-stage development product candidates and a fourth in Phase 1 clinical development.
"Peter Milner provided the vision that built a highly productive and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
More Articles from Mental Health Business Week
- Homewatch CareGivers
"National Caregiver of the Year" Award Winner Announced at Homewatch CareGivers' Annual Conference - Pennsylvania State Police Department
16 Die in Holiday Crashes Investigated by State Police - Alkermes
Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences - The Social Research Unit
As Government Slashes Spending, US Expert Advises UK on how to Spare Children From Worst Outcomes - More from this issue of Mental Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
